BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31065962)

  • 1. 50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.
    Letica-Kriegel AS; Leinwand JC; Sonett JR; Gorenstein LA; Taub RN; Chabot JA; Kluger MD
    Ann Surg Oncol; 2020 Jan; 27(1):205-213. PubMed ID: 31065962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peritoneal mesothelioma: the site of origin matters.
    Kindler HL
    Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
    Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant Peritoneal Mesothelioma: Patterns of Care and Survival in the Netherlands: A Population-Based Study.
    de Boer NL; van Kooten JP; Damhuis RAM; Aerts JGJV; Verhoef C; Madsen EVE
    Ann Surg Oncol; 2019 Dec; 26(13):4222-4228. PubMed ID: 31620941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current trends in the management of malignant peritoneal mesothelioma.
    Miura JT; Johnston FM; Gamblin TC; Turaga KK
    Ann Surg Oncol; 2014 Nov; 21(12):3947-53. PubMed ID: 24841356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
    Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
    Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases.
    Kyang LS; Alzahrani NA; Valle SJ; Rahman MK; Arrowaili A; Liauw W; Morris DL
    J Surg Oncol; 2019 Sep; 120(4):794-802. PubMed ID: 31309588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy.
    Heller DR; Chiuzan C; Taub RN; Leinwand JC; Greene AM; Bates GE; Chabot JA; Kluger MD
    Ann Surg Oncol; 2017 Dec; 24(13):3818-3824. PubMed ID: 29027138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania.
    Spatola C; Militello C; Tocco A; Salamone V; Luigi R; Migliore M; Marletta D; Cannizzaro A; Bevilacqua R; Milone P; Pergolizzi S; Privitera G
    Future Oncol; 2018 Mar; 14(6s):17-21. PubMed ID: 29400553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
    Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
    Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicystic and diffuse malignant peritoneal mesothelioma in children.
    Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study.
    Baratti D; Kusamura S; Cabras AD; Deraco M
    Ann Surg Oncol; 2012 May; 19(5):1416-24. PubMed ID: 22302266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
    Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
    Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
    Gómez Portilla A; Cendoya I; Muriel J; Olabarria I; Guede N; Moraza N; Fernández E; Martínez de Lecea C; Magrach L; Martín E; Romero E; Aguado I; Valdovinos M; Larrabide I
    Cir Esp; 2007 Feb; 81(2):82-6. PubMed ID: 17306123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.